Pulmatrix

Pulmatrix EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Pulmatrix (PULM) as of Nov 2, 2026 is -0.73. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was 0.17 — a change of -526.11% (lower).

EV/EBITDA

-0.73

YoY

-526.11%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Pulmatrix is 2025 -0.73 . EV/EBITDA (Enterprise Value to EBITDA) of Pulmatrix was 2024 0.17 . It decreases by -526.11% lower compared to the previous year.

The Pulmatrix EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2018
-0.26 USD
Jan 1, 2019
0.72 USD
Jan 1, 2020
2.24 USD
Jan 1, 2021
2.17 USD
Jan 1, 2022
1.42 USD
Jan 1, 2023
0.17 USD
Jan 1, 2024
0.17 USD
Jan 1, 2025
-0.73 USD
The Pulmatrix EV/EBITDA history
YEAREV/EBITDAYoY
-0.73-526.11%
0.17-1.77%
0.17-87.75%
1.42-34.43%
2.17-3.14%
2.24+210.40%
0.72-381.20%
-0.26-40.47%
-0.43+35.98%
-0.32-268.36%
0.19-105.34%
-3.52—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pulmatrix Stock analysis

What does Pulmatrix do? Pulmatrix, Inc. generates revenue through the development and commercialization of inhaled therapeutic products for respiratory diseases. The company focuses on its proprietary iSPERSE dry powder delivery technology, which enables the delivery of small or large molecule drugs to the lungs via inhalation. Pulmatrix's therapeutic candidates include Pulmazole, PUR1800, PUR5700, PUR3000, and PUR4000, designed to address serious respiratory conditions. The company targets healthcare providers and pharmaceutical partners seeking innovative inhaled therapies for respiratory diseases. Pulmatrix's business model relies on the development of its iSPERSE technology, which is compatible with various dry powder inhaler devices and can be formulated with small molecules and biologics. The company's product pipeline consists of multiple therapeutic candidates, each representing a potential revenue stream once approved. Pulmatrix aims to partner with pharmaceutical companies to advance its drug candidates through clinical trials and eventual market entry. The company's revenue streams are derived from the potential sale of its inhaled therapeutic products, which are developed using its iSPERSE platform. Pulmatrix's focus on respiratory diseases positions it to serve patients requiring novel treatments for conditions such as asthma, COPD, and other lung-related disorders. The company's clinical stage status indicates that its products are still in development, with commercialization expected upon regulatory approval. Pulmatrix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pulmatrix stock

EV/EBITDA (Enterprise Value to EBITDA) of Pulmatrix is -0.73 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of Pulmatrix changed from 0.17 to -0.73, representing a -526.11% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Pulmatrix since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Pulmatrix with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Pulmatrix

All Key Metrics — Pulmatrix